Log In
Print
BCIQ
Print
Print this Print this
 

adalimumab-Pfizer (PF-06410293)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionBiosimilar of adalimumab, a human mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today